The Journal of Immunology, Vol 132, Issue 3 1208-1215, Copyright © 1984 by American Association of Immunologists

ARTICLES

Cytokinetic basis for the impaired activation of lymphocytes from patients with primary intracranial tumors

LH Elliott, WH Brooks and TL Roszman

Patients with malignant brain tumors have a variety of immunologic abnormalities, including the impaired responsiveness of peripheral blood lymphocytes (PBL) to mitogens and alloantigens. We further investigated this impairment of lymphocyte reactivity by employing the techniques of limiting dilution analysis and cytokinetic analysis. PBL preparations from patients have approximately six times fewer phytohemagglutinin (PHA)-responsive cells than PBL from normal subjects. Similar results were obtained with purified T cell preparations. Cytokinetic analysis of PHA-induced [3H]thymidine incorporation employing colchicine blocking of mitosis demonstrated that the number of first generation cells entering the S-phase of mitosis for each 24-hr period was less for PBL from patients than for PBL from normal individuals. First generation responding cells from patients and normal subjects entered DNA synthesis at the same time (48 to 72 hr). Cytokinetic analysis over a period of 168 hr demonstrated that whereas PBL from normal individuals demonstrated second generation responding cells, PBL from the majority of patients did not, thus indicating a defect in their ability to undergo clonal expansion. Measurement of interleukin 2 (IL 2) activity in culture fluids from PHA- activated PBL from normal subjects and patients revealed significantly lower IL 2 levels in culture fluids from PBL from patients. The addition of various concentrations of lectin-free IL 2 to PBL from patients stimulated with PHA did not restore responsiveness to normal values. There was no difference between the levels of interleukin 1 (IL 1) produced by lipopolysaccharide-activated monocytes from normal subjects and patients. Overall, these results suggest that an intrinsic defect exists in T cells obtained from brain tumor patients that renders them unable to enter into normal mitogen-induced blastogenesis.

This article has been cited by other articles:

				C. J. Wheeler, K. L. Black, G. Liu, M. Mazer, X.-x. Zhang, S. Pepkowitz, D. Goldfinger, H. Ng, D. Irvin, and J. S. Yu Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme Patients Cancer Res., July 15, 2008; 68(14): 5955 - 5964. [Abstract] [Full Text] [PDF]

				C. A. Learn, P. E. Fecci, R. J. Schmittling, W. Xie, I. Karikari, D. A. Mitchell, G. E. Archer, Z. Wei, H. Dressman, and J. H. Sampson Profiling of CD4+, CD8+, and CD4+CD25+CD45RO+FoxP3+ T Cells in Patients with Malignant Glioma Reveals Differential Expression of the Immunologic Transcriptome Compared with T Cells from Healthy Volunteers Clin. Cancer Res., December 15, 2006; 12(24): 7306 - 7315. [Abstract] [Full Text] [PDF]

				P. E. Fecci, D. A. Mitchell, J. F. Whitesides, W. Xie, A. H. Friedman, G. E. Archer, J. E. Herndon II, D. D. Bigner, G. Dranoff, and J. H. Sampson Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res., March 15, 2006; 66(6): 3294 - 3302. [Abstract] [Full Text] [PDF]

				A. Chahlavi, P. Rayman, A. L. Richmond, K. Biswas, R. Zhang, M. Vogelbaum, C. Tannenbaum, G. Barnett, and J. H. Finke Glioblastomas Induce T-Lymphocyte Death by Two Distinct Pathways Involving Gangliosides and CD70 Cancer Res., June 15, 2005; 65(12): 5428 - 5438. [Abstract] [Full Text] [PDF]

				J. Schmielau and O. J. Finn Activated Granulocytes and Granulocyte-derived Hydrogen Peroxide Are the Underlying Mechanism of Suppression of T-Cell Function in Advanced Cancer Patients Cancer Res., June 1, 2001; 61(12): 4756 - 4760. [Abstract] [Full Text] [PDF]

				J.-P. Zou, L. A. Morford, C. Chougnet, A. R. Dix, A. G. Brooks, N. Torres, J. D. Shuman, J. E. Coligan, W. H. Brooks, T. L. Roszman, et al. Human Glioma-Induced Immunosuppression Involves Soluble Factor(s) That Alters Monocyte Cytokine Profile and Surface Markers J. Immunol., April 15, 1999; 162(8): 4882 - 4892. [Abstract] [Full Text] [PDF]